Ekso Bionics Q1 revenues hit record $4.1M, up 61% YoY; net loss narrows to $4.4M

EKSO BIONICS HOLDINGS, INC.

2023-Q1 EPS reported -$0.33 revenue$4,122,000

Revenue of $4.1M, a 61% increase from $2.6M in Q1 2022; gross margin improved to 49% from 47%.
Net loss of $4.4M ($0.33 per share) vs. $4.6M ($0.36 per share) in Q1 2022.
Booked 23 EksoHealth devices in Q1; cash position $16.3M at March 31, 2023.
Sales & marketing spend rose to $2.1M from $1.6M, reflecting HMC acquisition costs.
CEO cites multi-unit orders with large network operators and Indego product line contributions.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

EKSO BIONICS HOLDINGS, INC. reported three months ended March 31, 2023 results: revenue $4.1 million, net income $4.4 million, EPS $0.33 per basic and diluted share.

Period: three months ended March 31, 2023
Revenue: $4.1 million
Net income: $4.4 million
EPS: $0.33 per basic and diluted share
Result: reported results

Exact text from the filing

for medical and industrial use, today reported financial results for the three months ended March 31, 2023. Recent Highlights and Accomplishments • Achieved record revenues of $4.1 million in the first quarter of 2023, up 61% from the first quarter of 2022 • Delivered products across continuum of care following the addition of the Indego ® product line • Booked a

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

EKSO BIONICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001549084-23-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.